{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T14:33:05Z","timestamp":1791469985935,"version":"4.3.4"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T00:00:00Z","timestamp":1751068800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2214050003863"],"award-info":[{"award-number":["2214050003863"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010256","name":"Guangzhou Municipal Science and Technology Project","doi-asserted-by":"publisher","award":["2023A04J0616"],"award-info":[{"award-number":["2023A04J0616"]}],"id":[{"id":"10.13039\/501100010256","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010256","name":"Guangzhou Municipal Science and Technology Project","doi-asserted-by":"publisher","award":["2024A03J1022"],"award-info":[{"award-number":["2024A03J1022"]}],"id":[{"id":"10.13039\/501100010256","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.tranon.2025.102467","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T12:09:09Z","timestamp":1751976549000},"page":"102467","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Sitravatinib combined with venetoclax exerts effective synergy to eliminate acute myeloid leukemia cells with FLT3-ITD mutations"],"prefix":"10.1016","volume":"59","author":[{"given":"Jie","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvyin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingshan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6899-8765","authenticated-orcid":false,"given":"Peihong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7382","key":"10.1016\/j.tranon.2025.102467_bib0001","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nature10738","article-title":"Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing","volume":"481","author":"Ding","year":"2012","journal-title":"Nature"},{"issue":"23","key":"10.1016\/j.tranon.2025.102467_bib0002","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.tranon.2025.102467_bib0003","first-page":"6766","article-title":"Prognosis and outcome of patients with acute myeloid leukemia based on FLT3\u2011ITD mutation with or without additional abnormal cytogenetics","volume":"18","author":"Tao","year":"2019","journal-title":"Oncol. Lett."},{"issue":"6","key":"10.1016\/j.tranon.2025.102467_bib0004","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/leu.2011.25","article-title":"A new Leukemia prognostic Scoring system for refractory\/relapsed adult acute myelogeneous leukaemia patients: a GOELAMS study","volume":"25","author":"Chevallier","year":"2011","journal-title":"Leukemia"},{"issue":"22","key":"10.1016\/j.tranon.2025.102467_bib0005","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.tranon.2025.102467_bib0006","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1182\/blood-2014-10-605808","article-title":"Secondary mutations as mediators of resistance to targeted therapy in leukemia","volume":"125","author":"Daver","year":"2015","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.tranon.2025.102467_bib0007","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1158\/2159-8290.CD-13-0609","article-title":"Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia","volume":"4","author":"Pan","year":"2014","journal-title":"Cancer Discov."},{"issue":"3","key":"10.1016\/j.tranon.2025.102467_bib0008","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.stem.2012.12.013","article-title":"BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells","volume":"12","author":"Lagadinou","year":"2013","journal-title":"Cell Stem Cell"},{"issue":"1","key":"10.1016\/j.tranon.2025.102467_bib0009","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.tranon.2025.102467_bib0010","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1038\/s41375-019-0612-8","article-title":"How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia","volume":"33","author":"Jonas","year":"2019","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.tranon.2025.102467_bib0011","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/ajh.25000","article-title":"Clinical experience with the BCL 2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies","volume":"93","author":"DiNardo","year":"2018","journal-title":"Am. J. Hematol."},{"issue":"24","key":"10.1016\/j.tranon.2025.102467_bib0012","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1182\/blood.2021014241","article-title":"Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1","volume":"140","author":"Janssen","year":"2022","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.tranon.2025.102467_bib0013","doi-asserted-by":"crossref","first-page":"6815","DOI":"10.1158\/1078-0432.CCR-19-0832","article-title":"Inhibition of bcl-2 synergistically enhances the antileukemic activity of Midostaurin and Gilteritinib in preclinical models of FLT3-mutated acute myeloid leukemia","volume":"25","author":"Ma","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.tranon.2025.102467_bib0014","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40364-022-00447-4","article-title":"Sitravatinib as a potent FLT3 inhibitor can overcome gilteritinib resistance in acute myeloid leukemia","volume":"11","author":"Zhang","year":"2023","journal-title":"Biomark. Res."},{"issue":"1","key":"10.1016\/j.tranon.2025.102467_bib0015","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1038\/s41467-023-38342-7","article-title":"Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma","volume":"14","author":"Karam","year":"2023","journal-title":"Nat. Commun."},{"issue":"641","key":"10.1016\/j.tranon.2025.102467_bib0016","doi-asserted-by":"crossref","first-page":"eabm6420","DOI":"10.1126\/scitranslmed.abm6420","article-title":"A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy","volume":"14","author":"Msaouel","year":"2022","journal-title":"Sci. Transl. Med."},{"issue":"7","key":"10.1016\/j.tranon.2025.102467_bib0017","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.jtho.2023.02.016","article-title":"MRTX-500 phase 2 trial: sitravatinib with Nivolumab in patients with nonsquamous NSCLC progressing on or after checkpoint inhibitor therapy or chemotherapy","volume":"18","author":"He","year":"2023","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.tranon.2025.102467_bib0018","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.annonc.2023.10.004","article-title":"SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"35","author":"Borghaei","year":"2024","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.tranon.2025.102467_bib0019","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1158\/1078-0432.CCR-22-3351","article-title":"A single-arm phase II trial of Sitravatinib in advanced well-differentiated\/dedifferentiated liposarcoma","volume":"29","author":"Ingham","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.tranon.2025.102467_bib0020","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1007\/s10637-022-01274-y","article-title":"First-in-human phase 1\/1b study to evaluate sitravatinib in patients with advanced solid tumors","volume":"40","author":"Bauer","year":"2022","journal-title":"Invest. New Drugs"},{"issue":"2","key":"10.1016\/j.tranon.2025.102467_bib0021","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006055","article-title":"SAFFRON-103: a phase 1b study of the safety and efficacy of sitravatinib combined with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer","volume":"11","author":"Zhao","year":"2023","journal-title":"J. ImmunOther Cancer"},{"key":"10.1016\/j.tranon.2025.102467_bib0022","article-title":"A phase 2 study of Sitravatinib in combination with Nivolumab in patients with advanced or metastatic urothelial carcinoma","author":"Msaouel","year":"2023","journal-title":"Eur. Urol. Oncol."},{"issue":"4","key":"10.1016\/j.tranon.2025.102467_bib0023","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2217\/imt-2023-0130","article-title":"SAFFRON-103: a phase ib study of sitravatinib plus tislelizumab in anti-PD-(L)1 refractory\/resistant advanced melanoma","volume":"16","author":"Wang","year":"2024","journal-title":"Immunotherapy."},{"issue":"21","key":"10.1016\/j.tranon.2025.102467_bib0024","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1182\/blood.2022015853","article-title":"Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia","volume":"140","author":"Duncavage","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2025.102467_bib0025","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.19519","article-title":"Combination therapy with novel agents for acute myeloid leukaemia: insights into treatment of a heterogenous disease","author":"Jen","year":"2024","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.tranon.2025.102467_bib0026","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/s41375-021-01425-9","article-title":"Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries","volume":"36","author":"Recher","year":"2022","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.tranon.2025.102467_bib0027","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1200\/JCO.2007.15.4245","article-title":"Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group","volume":"27","author":"Buchner","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.tranon.2025.102467_bib0028","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11912-024-01503-y","article-title":"Novel therapeutic targets in acute myeloid leukemia (AML)","volume":"26","author":"Wysota","year":"2024","journal-title":"Curr. Oncol. Rep."},{"issue":"5","key":"10.1016\/j.tranon.2025.102467_bib0029","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.tips.2024.03.005","article-title":"AML treatment: conventional chemotherapy and emerging novel agents","volume":"45","author":"Forsberg","year":"2024","journal-title":"Trends. Pharmacol. Sci."},{"issue":"3","key":"10.1016\/j.tranon.2025.102467_bib0030","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_438662","article-title":"Advancements and challenges in the treatment of AML","volume":"44","author":"Abaza","year":"2024","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"issue":"7","key":"10.1016\/j.tranon.2025.102467_bib0031","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.tranon.2025.102467_bib0032","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov."},{"issue":"13","key":"10.1016\/j.tranon.2025.102467_bib0033","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1158\/1078-0432.CCR-20-4271","article-title":"FDA approval summary: gilteritinib for relapsed or refractory acute myeloid leukemia with a FLT3 mutation","volume":"27","author":"Pulte","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"10388","key":"10.1016\/j.tranon.2025.102467_bib0034","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","article-title":"Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Erba","year":"2023","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.tranon.2025.102467_bib0035","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/S1470-2045(20)30455-1","article-title":"Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial","volume":"21","author":"Xuan","year":"2020","journal-title":"Lancet Oncol."},{"issue":"18","key":"10.1016\/j.tranon.2025.102467_bib0036","first-page":"15","article-title":"Mechanisms of resistance to small molecules in acute myeloid leukemia","author":"Lang","year":"2023","journal-title":"Cancers. (Basel)"},{"issue":"6","key":"10.1016\/j.tranon.2025.102467_bib0037","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41408-022-00687-5","article-title":"Resistance to targeted therapies: delving into FLT3 and IDH","volume":"12","author":"Desikan","year":"2022","journal-title":"Blood Cancer J."},{"issue":"3","key":"10.1016\/j.tranon.2025.102467_bib0038","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41573-022-00615-z","article-title":"Rational combinations of targeted cancer therapies: background, advances and challenges","volume":"22","author":"Jin","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"issue":"35","key":"10.1016\/j.tranon.2025.102467_bib0039","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1200\/JCO.22.00602","article-title":"Venetoclax plus gilteritinib for FLT3-mutated relapsed\/refractory acute myeloid leukemia","volume":"40","author":"Daver","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.tranon.2025.102467_bib0040","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41392-021-00578-4","article-title":"FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3\/ITD acute leukemia cells through BIM activation","volume":"6","author":"Zhu","year":"2021","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"4","key":"10.1016\/j.tranon.2025.102467_bib0041","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/bjh.19314","article-title":"Venetoclax resistance in acute myeloid leukaemia-clinical and biological insights","volume":"204","author":"Nachmias","year":"2024","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.tranon.2025.102467_bib0042","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1158\/2643-3230.BCD-20-0143","article-title":"Patterns of resistance differ in patients with acute myeloid leukemia treated with type I versus Type II FLT3 inhibitors","volume":"2","author":"Alotaibi","year":"2021","journal-title":"Blood Cancer Discov."},{"issue":"39","key":"10.1016\/j.tranon.2025.102467_bib0043","doi-asserted-by":"crossref","first-page":"5119","DOI":"10.1038\/onc.2016.41","article-title":"Aberrant activation of the PI3K\/mTOR pathway promotes resistance to sorafenib in AML","volume":"35","author":"Lindblad","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.tranon.2025.102467_bib0044","article-title":"Mechanisms of venetoclax resistance and solutions","volume":"12","author":"Liu","year":"2022","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.tranon.2025.102467_bib0045","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.3324\/haematol.2019.244020","article-title":"Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models","volume":"106","author":"Singh Mali","year":"2021","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.tranon.2025.102467_bib0046","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/cac2.12040","article-title":"Modulating the function of ABCB1: in vitro and in vivo characterization of sitravatinib, a tyrosine kinase inhibitor","volume":"40","author":"Yang","year":"2020","journal-title":"Cancer Commun. (Lond)"},{"key":"10.1016\/j.tranon.2025.102467_bib0047","doi-asserted-by":"crossref","first-page":"700","DOI":"10.3389\/fonc.2020.00700","article-title":"Sitravatinib, a tyrosine kinase inhibitor, inhibits the transport function of ABCG2 and restores sensitivity to chemotherapy-resistant cancer cells in vitro","volume":"10","author":"Yang","year":"2020","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.tranon.2025.102467_bib0048","doi-asserted-by":"crossref","first-page":"5709","DOI":"10.1038\/s41467-023-41229-2","article-title":"ABCC1 and glutathione metabolism limit the efficacy of BCL-2 inhibitors in acute myeloid leukemia","volume":"14","author":"Ebner","year":"2023","journal-title":"Nat. Commun."}],"updated-by":[{"DOI":"10.1016\/j.tranon.2026.102798","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000}},{"DOI":"10.1016\/j.tranon.2026.102798","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000}}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523325001986?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523325001986?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T20:05:43Z","timestamp":1780862743000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523325001986"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":48,"alternative-id":["S1936523325001986"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2025.102467","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sitravatinib combined with venetoclax exerts effective synergy to eliminate acute myeloid leukemia cells with FLT3-ITD mutations","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2025.102467","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. CCBYLICENSE","name":"copyright","label":"Copyright"}],"article-number":"102467"}}